HIGH HOMOCYSTEINE SERUM LEVELS AS A CAUSE OF EARLY AND MASSIVE ATHEROSCLEROSIS: VITAMINS B-6-9-12 SUPPLEMENTATION: MORE SHADOWS THAN LIGHTS

Federico Cacciapuoti

Folic acid and/or Vitamins B-6-12 deficiency induces high-homocysteine (H-Hcy) serum levels for reduced activity of methylene-tetra hydro folate reductase (MTHFR). This metabolic derangement can be responsible for early and massive atherosclerosis, that could favour ischemic acute events. It can be assumed that vitamins’ supplementation, reducing the elevated Hcy serum concentration, could reduce atherosclerotic risk. In this review, we evaluated if, the reduction of the high Hcy values by the B-vitamins’ supplementation, is able to reduce the incidence of atherosclerotic events. Retrospective trials performed in patients already suffered of acute ischemic episodes, demonstrated that vitamins B-6-12 supplementation was unable to reduce the incidence of new ischemic events, even if it lowers the high Hcy levels. On the contrary, prospective studies carried out in patients not previously suffered of cardiovascular acute events, evidenced that the vitamins’ supplementation significantly reduced both Hcy serum concentration and atherosclerotic risk.

These conflicting results demonstrate that folic acid and vitamins B-12 supplementation is effective in to reduce high Hcy serum concentration in patients with signs of previous atherosclerosis, but is unable to reduce the atherosclerotic risk. On the contrary, the supplementation is useful in to lower both high Hcy serum levels and atherosclerotic risk in patients without atherosclerotic marks. In addition, some experiences performed in this field demonstrated that these nutrients could favor some negative effects, as the growth of an unknown neoplastic mass, especially the cells of prostate cancer.

Therefore, the supplementation with folates and other vitamins of B group can be performed cautiously in patients with increased Hcy serum concentration.

Key words: Homocysteine; Ischemic risk; Folate and B-12 vitamins supplementation

© 2016 The Author. Published by ACT Publishing Group Ltd.

Cacciapuoti F. High Homocysteine Serum Levels as A Cause of Early and Massive Atherosclerosis: Vitamins B-6-9-12 Supplementation: More Shadows Than Lights. Journal of Cardiology and Therapy 2016; 3(4): 549-553 Available from: URL: http://www.ghrnet.org/index.php/jct/article/view/1811

INTRODUCTION

Apart from traditional risk factors for cardiovascular disease, a powerful cause for raised cardiovascular morbidity and mortality can be the inherited or acquired hyper-homocysteinemia (H-Hcy). In this field, several reports referred that H-Hcy can be responsible for early and massive atherosclerosis, inducing some vascular diseases life threatening, such as myocardial infarction (MI), ischemic acute stroke (IS), and peripheral vascular disease (PVD)[1-5]. Concerning this, several studies and trials demonstrated that elevated plasma total Hcy may promote atherothrombosis with several mechanisms[6-8]. Among these, increased Hcy and S-adenosyl-homocysteine (SAH) serum values, inhibiting the methyltransferases, result in abnormal smooth muscle cell proliferation and reduction of endothelial cells’ growth. A critical role in the atherosclerotic process is played by DNA hypomethylation[9,10]. But, H-Hcy also causes down regulation of cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE), resulting in depletion of H2S, an angiogenic agent with antioxidant and vasorelaxing properties. Therefore, its depletion results in
Homocysteine metabolism: three pathways. MTHFR: Methylene-Tetra-Hydrofolate-Reductase; MAT: Methionine-Adenosyl-Transferase; SAM: S-Adenosyl-Methionine; SAH: S-Adenosyl-Homocysteine; SAHH: SAH-Hydrolase; CBS: Cystationine-Beta-Synthase; CGL: Cystationine-Gamma-Lyase; BHMT: Betaine-Methionine-Transferase.

There are three pathways that maintain low serum levels concentration of Hcy. The first involves the methylation of Hcy and is catalyzed by methionine synthase (MS). In this, Hcy is converted into Methionine by the enzyme $^{[5,9]}$ methylene-tetra-hydrofolate-dereductase (MTHFR) requiring folic acid and vitamin $B_6$ as cofactors. In turn, Methionine (reacting with ATP) forms S-adenosyl-methionine (SAM), the principal cellular methyl donor. Giving its methyl-group (C-H3), SAM is converted in S-adenosyl-homocysteine (SAH). Inside cells, SAH is turned in Hcy by the enzyme SAH-hydrolase. But, when intracellular Hcy concentration increased, the SAH-hydrolase reaction proceeds in favor of SAH formation. In this connection, Yi and others provided evidence that moderate Hcy increases were highly correlated with elevations in plasma SAH.

In the trans-sulfuration pathway (second metabolization pathway), Hcy can be irreversibly converted in cystathionine by the enzyme cystationine-$\beta$-synthase (CBS), requiring vitamin $B_6$ as co-enzyme. Subsequently, cystathionine is metabolized into cysteine, a precursor for glutathione. This same is a powerful antioxidant, acting against oxidative damage.

A third route of Hcy metabolism happens in kidney and liver alone. In that, Hcy is remethylated by the enzyme betaine homocysteine methyl-transferase (BHMT), requiring vitamin $B_6$ as cofactor. BHMT transfers a methyl group from betaine to Hcy, producing dimethylglycine (DMG) and Methionine respectively (Figure 1).

Conclusively, Hcy metabolism requires three co-enzymes (cofactors) as folic acid ($B_9$), vitamin $B_12$ (cobalamin), and vitamin $B_6$ (pyridoxal phosphate). Folic acid is a substrate for production of 5-methyltetrahydrofolate (MTHF). Vitamin $B_12$ is required, as cofactor, for MS activity. Vitamin $B_6$ is a cofactor for CBS and BMHT.

Multiple experiences evidenced that the reduced presence/action of these cofactors causes an increase of Hcy levels, responsible for increased trend to early and massive atherosclerotic lesions. In this connection, it was hypothesized that folate and $B_{12}$ vitamins supplementation is useful in to lower both Hcy elevated serum levels and atherosclerotic trend$^{[10]}$. But, contrary to the expected results, large controlled trials have found that this supplementation, even through lowers Hcy levels, does not significantly reduce the incidence of cardiac, peripheral and cerebro-vascular atherosclerotic events. Concerning that, the Vitamin for Stroke Prevention (VISP) study, a multicenter randomized non-placebo trial performed in patients with a history of previous ischemic stroke, demonstrated that both low (2.0 mg. of folate, 20 mg. of $B_6$, 6 mcg. of $B_{12}$) or high (2.5 mg. of folate, 25 mg. of $B_6$, 400 mg. of $B_{12}$) doses of folate and $B_{12}$ vitamins are unable to prevent ischemic acute events, even if lowers high Hcy levels$^{[10]}$. In the Heart Outcomes Prevention Evaluation (HOPE) 2 study, 5522 patients with pre-existing cardiovascular disease (CVD) were randomly assigned to Hcy-lowering therapy and treated with folate and $B$ vitamins (2.5 mg of folate, 50 mg. of $B_6$, 1 mg of $B_{12}$ or placebo. After a five-year follow-up, in this study also no differences in cardiovascular disease or cardiovascular death between the treated and placebo group was found, despite lowering of Hcy levels$^{[10]}$. These findings were consistent with the results obtained in the Norwegian Vitamin Intervention Trial (NORVIT). The trial evaluated 3749 patients with recent myocardial infarction (MI). Patients were randomly assigned to respectively receive either folate plus vitamin $B_6$ (group I); folate (0.8 mg/day) plus vitamin $B_6$ (0.4 mg/day) (group II); vitamin $B_6$ (40 mg/day) alone (group III) or placebo (group IV). At the end of the trial, no significant differences in MI, stroke or sudden cardiac death were detected among any of the four groups. Referring to these results, the authors concluded that the active treatment with folates and $B$-vitamins is not recommended$^{[21]}$.

Previously, the VITATOPS (VitaMins TO Prevent Stroke) study, a multicenter, randomized, double blind, placebo controlled secondary stroke prevention trial, was performed to determine whether the addition of vitamins $B_{9-12}$ is able to reduce the combined incidence of vascular events (stroke, MI) and vascular death in patients with recent stroke or TIA. In this trial too, the results obtained showed that vitamins $B_{9-12}$ supplementation (2 mg of folate, 25 mg of $B_6$, 0.5 mg of $B_{12}$) is safe but not statistically significantly in reducing the risk of major vascular events$^{[21]}$. In accordance, a meta-analysis of several randomized, controlled trials performed by Bazzano et al concluded that folic acid supplementation did not reduce the risk of CVD and all cause mortality among participants with prior history of CVD$^{[22]}$.

In the trans-sulfuration pathway, for hypercoagulable state and a higher risk of thrombosis characterizing HHcy-patients. Therefore, increased plasma Hcy levels may increase cardiovascular risk by increasing thrombotic tendency$^{[15,16]}$. In the trans-sulfuration pathway, for hypercoagulable state and a higher risk of thrombosis characterizing HHcy-patients. Therefore, increased plasma Hcy levels may increase cardiovascular risk by increasing thrombotic tendency$^{[15,16]}$. In the trans-sulfuration pathway, for hypercoagulable state and a higher risk of thrombosis characterizing HHcy-patients. Therefore, increased plasma Hcy levels may increase cardiovascular risk by increasing thrombotic tendency$^{[15,16]}$. In the trans-sulfuration pathway, for hypercoagulable state and a higher risk of thrombosis characterizing HHcy-patients. Therefore, increased plasma Hcy levels may increase cardiovascular risk by increasing thrombotic tendency. In the trans-sulfuration pathway, for hypercoagulable state and a higher risk of thrombosis characterizing HHcy-patients. Therefore, increased plasma Hcy levels may increase cardiovascular risk by increasing thrombotic tendency. In the trans-sulfuration pathway, for hypercoagulable state and a higher risk of thrombosis characterizing HHcy-patients. Therefore, increased plasma Hcy levels may increase cardiovascular risk by increasing thrombotic tendency. In the trans-sulfuration pathway, for hypercoagulable state and a higher risk of thrombosis characterizing HHcy-patients. Therefore, increased plasma Hcy levels may increase cardiovascular risk by increasing thrombotic tendency.

Cacciapuoti F. Homocysteine and cardiovascular risk: vitamins B6-9-12 supplementation.
Contrarily to these retrospective trials, a meta-analysis of prospective observational studies showed that 25% lower Hcy levels was associated with an 11% lower ischemic heart disease risk and a 19% lower stroke risk[20]. In addition, Wald et al have evaluated 20 prospective studies and concluded that lowering Hcy concentration by 3 μmol/L decreased the risk of ischemic heart disease by 16% and stroke by 24%[21]. Other studies have reported that folic acid supplementation has been found to improve endothelial function, a surrogate end point for cardiovascular risk, both in healthy and in patients with H-Hcy[22-29].

The conflicting results obtained in these studies are summarized in Table 1. The exact mechanisms underlying the ameliorative effects on atherosclerotic risk obtained in the last studies are still unknown. Perhaps, this effect may be reported to an independent lowering-Hcy mechanism and could referred to direct pharmacological actions of Vitamins B6-9-12 on atherosclerosis, rather than to indirect consequence of the reduction in Hcy serum levels. Likely, 5-methyl tetrahydrofolate (a derived compound of folic acid) improves nitric oxide production and prevents superoxide generation, via uncoupling of nitric oxide synthase by stabilizing tetrahydrobiopterin or regenerating this same from its inactive form[30-31]. In confirmation of that, a study of Doshi et al provides evidence indicating that an improvement in endothelial function (assessed by flow-mediated dilatation) was observed after the first dose of folic acid and was present before any significant reduction in Hcy serum levels. This observation demonstrated that the improvement in endothelial function is due to direct pharmacological actions of folic acid rather than reductions inHcy concentrations[32]. Another folate study performed more recently confirmed that daily supplementation of oral folic acid improves arterial function in patients with peripheral arterial disease[33]. Concerning this, a randomized study conducted in 103 patients at increased risk of stroke, investigated the effect of folic acid supplementation on carotid intima-media thickness (IMT). After 18 months of folic acid (vitamin B) supplementation, a significant regression of carotid IMT in the treated group compared to IMT progression recorded in the placebo group was found[34]. Similar results were reported in a study examining the influence of folic acid on carotid artery atherosclerosis. Another perspective study showed an inverse association between plasma folate and plaque calcification score[35]. In addition, a recent analysis of multiple studies suggests that folic acid supplementation can reduce the risk of stroke in people with H-Hcy who have not already suffered a stroke, but did not reduce the risk of second stroke in people who have already had one. This observation raises the possibility that Hcy lowering is beneficial at early stages of vascular disease elaboration, but is less effective in the face of established advanced disease[36]. An improvement of flow-mediated dilatation was also found in hyperomocysteinemic patients with unstable angina[37]. Finally, Kolling et al described that folic acid supplementation is useful in to prevent Hcy-induced peroxidation, ROS production, antioxidiant and NO reduction in rats[38]. On the contrary, the negative results on cardiovascular risk reported in studies previously performed by vitamins B supplementation in patients with HHcy serum levels must be referred to numerous design and methodological flaws including limited statistical power, and relatively short duration of follow-up in pts. evaluated. It must be also added that these trials were addressed to secondary prevention of atherosclerotic acute events. On the contrary, the Hcy-lowering with folate and vitamins B12, supplementation could play a more important role in to reduce atherosclerotic risk in the primary prevention. It must be also added that the reversion of an atherosclerotic process in patients already suffered of ischemic acute events is more difficult. It must also be added that, although folate and vitamins B12, supplementation lowers Hcy levels, they may simultaneously increase atherosclerotic risk through other Hcy-independent mechanisms. Concerning this, an editorial by Loscalzo postulated that folic acid and B vitamins supplementation may even promote atherosclerosis, by increasing cell proliferation in atherosclerotic plaques enhancing methylation of DNA, and augmenting levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthesis[39,40]. Another possibility for explain the negative results is that H-Hcy is a clinically important risk factor only when plasma Hcy is elevated to extremely high levels, but it is less important for light or mild H-Hcy, as happens in the greatest number of patients with H-Hcy[41-43]. In confirmation of that, in contrast to the evident clinical benefits of Hcy-lowering therapy obtained in patients with severe H-Hcy, in those with mild-moderate Hcy (values ranged between 15-30 μmol/L), the reduction of vascular risk is negligible by the B vitamins supplementation, although the Hcy concentration lowers[44].

**CONCLUSIVE REMARKS**

Referring to these conflicting results, we may affirm that the folic acid and B9-12 vitamins supplementation is useless when an acute ischemic event is already happened. On the contrary, this supplementation could efficaciously be carried out early, when the atherosclerotic lesions didn’t show yet. A further caution concerning the vitamins-B6-9-12 supply referred to some, frequent side effects, as black stools, diarrhea, incomplete or infrequent bowel movements, intense abdominal pain, depression or bronchospasm. It was also added that the supplementation must be given cautiously because of some contradictory published data suggesting that folic acid could induce the growth of neoplastic mass once constituted[45] or could favour its beginning. That can be caused byfylolate-mediated one-carbon metabolism (which involves B-vitamins), by inducing epigenomic changes and influencing the DNA synthesis[46]. Concerning this topic, it must be added that high folate concentrations were especially associated with increased prostate cell proliferation[47]. These limitations justify the uncertain about the folates and Vitamins B supplementation in to prevent the atherosclerotic marks in patients with increased Hcy serum levels.

In conclusion, the evidences of several studies published over two decades suggest that vitamins-B supplementation in patients suffering from H-Hcy could be a nontoxic and easy method in the primary prevention of CVD. On the contrary, its employment in the secondary prevention of atherosclerotic disease seems not to be indicated or heedless, even if the supplementation significantly reduces the high Hcy serum levels.

| Table 1 Results of B6-9-12 supplementation in several trials and meta-analyses |
|-----------------|----------------|----------------|-----------|
| VISP 2004[24]   | -              | -              | Stroke    |
| NORVIT 2006[25] | -              | -              | AMI       |
| HOPE-2 2006[26] | +              | +              | CVD       |
| VITATOPS 2010[27] | -          | -              | Sudden Death |
| Bazzano 2000[28] | -              | +              |            |
| Wald 2002[29]   | -              | +              |            |
| H.C.S. 2002[30] | +              | +              |            |
| Verhaar 2002[31] | -              | +              |            |
| Moat 2006[32]   | +              | +              |            |
| Moens 2007[33]  | +              | +              |            |
| Shirodaria 2007[34] | +      |                |            |
| Tian 2008[35]   | +              |                |            |

AMI: Acute Myocardial Infarction; CVD: Cardio-Vascular Disease; (-): negative results; (+): positive results.
CONFLICT OF INTERESTS

There are no conflicts of interest with regard to the present study.

REFERENCES

1. McCully KS. Hyperhomocysteinemia and atherosclerosis: historical perspectives. Clin. Chem. Lab Med 2005; 43: 980-986
2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 2002; 288: 2015-2022
3. Welch GN, Loscalzo J. Homocysteine and athero-thrombosis. N Engl J Med 1998; 338: 1042-1050
4. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Atheroscl. Thromb. Vasc. Biol 1997; 17: 1947-1953
5. Dornagla TB, Undas A, Libura M, Szczeklik A. Pathogenesis of vascular disease in hyper-homocysteinemia. J Cardiovasc Risk 1998; 5: 239-247
6. Dong C, Yoon W, Goldschmidt-Clermont PJ. DNA methylation and atherosclerosis. J Nutr 2002; 132: 2406S-2409S
7. James SJ, Melnik S, Pogribna M, Pogribny IP, Caudill MA. Epigenetic potential of S-adenosylhomocysteine and DNA hypomethylation: a potential mechanism for homocysteine-related pathology. J Nutr 2002; 132: 2361S-2366S
8. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 1996; 98: 5-7
9. Castro R, Rivera I, Struyfs EA, Jansen EEW, Ravasco P, Camilo ME, Blom HJ, Jakobs BC. Increased homocysteine and S-Adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem 2003; 49: 1292-1296
10. Varga EA, Strurm AC, Misita CP, Moll S. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease. Circulation 2005; 111: e289-e293
11. Sen U, Sathnur PB, Kundu S, Giwinski M, Coley DM, Mishra PK, Qipshidze, N; Tyagi, N; Metreveli, N; Tyagi, SC. Increased endogenous H2S generation by CBS, CSE and 2MST gene therapy improves ex vivo renovascular relaxation in hyperhomocysteinemia. Am J Cell Physiol 2012; 303: C41-C51
12. Jacobsen DW. Hyperhomocysteinemia and oxidative stress. Time for a reality check? Arterioscl. Thromb. Vasc. Biol 2000; 20: 1182-1184
13. Upchurch GR, Welch G, Fabian A, Fredman JE, Jonsson JL, Kerney JF, Loscalzo J. Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012-17017
14. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinemia and endothelial dysfunction. Lancet 1998; 351: 36-37
15. Ogawa M, Abe S, Salmo G, Biro S, Toda H, Matsouka T, Torii H, Minagoe S, Maruyama I, Tei C. Homocysteine and hemostatic disorder as a risk factor for myocardial infarction at young age. Thromb Res 2003; 109: 253-258
16. Undas A, Brozek J, Jankowski M, Siudak Z, Szczeklik A, Jakubowski H. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscl Thromb Vasc Biol 2006; 26: 1397-1404
17. Yi P, Melnik S, Pogribna M, Pogribny I, Hine RL, James SJ. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte hypomethylation. J Biol Chem 2000; 275: 29218-29223
18. Pietrzik K, Bonstrup A. The role of homocysteine, folate and other B-vitamins in the development of atherosclerosis. Arch Latinoam Nutr 1997; 47: 9-12
19. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stamper M. Lowering homocysteine in patients with ischemic stroke to prevent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-575
20. Lonn E, Yusuf S, Arnold MJ, Sideras P, McQueen J, Pogue J. Heart Outcomes Prevention Evaluation (HOPE 2) Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 355: 1567-1577
21. Bonaa KH, Nilsstad I, Ueland PM, Schimler H, Tverdal A, Steigen T, Wang H, Nordahlouge JE, Arnesen E, Rasmussen K, NORVIT trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. NEJM 2006; 354: 1578-1588
22. The VITATOPS (Vitamins to prevent stroke) trial: rationale and design of an international large, simple, randomized trial of homocysteine-lowering multivitamin therapy in patients with recent ischemic attack or stroke. Cerebrovasc Dese 2002; 13: 120-126
23. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases. A meta-analysis of randomized, controlled trials. JAMA 2006; 296: 2720-2726
24. Wald DS, Law M, Morris JK. Homocysteine and risk of ischemic heart disease and stroke: evidence on causality from a meta-analysis. Br Med Journ 2002; 288: 1202-1206
25. Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscl Thromb Vasc Biol 2002; 22: 6-13
26. Moat SJ, Madhavan A, Taylor SY, Payne N, Allen RH, Stabler SP, Goodfellow J, Mc Dowell F, Lewis MJ, Lang D. High but not low-dose folic acid improves endothelial function in coronary artery disease. Eur J Clin Invest 2006; 36: 850-859
27. Moens AL, Claeyes MJ, Wuys FL, Gooverts I, Herbruggen E, Wendelen LC, Van Houw V, Vrints J. Effect of folic acid on endothelial function following acute myocardial infarction. Am J Cardiol 2007; 99: 476-481
28. Shirodaria C, Antoniades C, Lee J, Jackson CE, Robson MD, Francis JM, Moat SJ, Ratnatunga C, Pillai R, Refsum H, Neuber S, Chanoon JM. Global improvement of vascular function and re dox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease. Circulation 2007; 115: 2262-2270
29. Tian R, Ingwall JS. How does folic acid cure heart attacks? Circulation 2008; 117: 1772-1774
30. Nakan E, Higgins JA, Powers HJ. Folate protects against oxidative modification of human LDL. Br J Nutr 2001; 86: 637-639
31. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, Leeson P, Neuber S, Ratnatunga C, Pillai R, Refsum H, Chanan KM, 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobipterin availability and endothelial nitric oxide synthase coupling. Circulation 2006; 114: 1193-1201
32. Doshi SN, Mc Dowell IF, Moat SJ, Payne N, Durrant KJ, Lewis MJ, Goodfellow J. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002; 105: 22-26
33. Khandanpour N, Arnon MP, Jennings B, Finglas PM, Wills G, Clark M, Meyer FJ. Randomized clinical trial of folic acid supplementation in patients with peripheral arterial disease. Br J Surg 2006; 93: 990-998
34. Niaios G, Savopoulos C, Karamostos D, Economou I, Destani E. The effect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk. A placebo-controlled trial. Int J Cardio 2010; 143: 16-19
35. Held C, Sumner G, Sheridan P, McQueen M, Smith S, Dangenais Cacciapuoti F. Homocysteine and cardiovascular risk: vitamins B6-9-12 supplementation
lowering therapy with folic acid in stroke prevention: a meta-analysis. Stroke 2010; 41: 1205-1212

37 Guo H, Chi J, Yangbo X, Ping W. Influence of folic acid on plasma homocysteine levels and arterial endothelial function in patients with unstable angina. Indian J Med Res 2009; 129: 279-284

38 Kolling J, Scherer EB, da Cunha AA, da Cunha MJ, Wyse AT. Homocysteine induces oxidative-stress in heart rats. Cardiovasc Toxicol 2011; 11: 67-73

39 Loscalzo J. Homocysteine trials-clear outcomes for complex reasons. N Engl J Med 2006; 354: 1629-1632

40 Loscalzo J. Adverse effects of supplemental L-arginine in atherosclerosis: consequences of methylation stress in a complex catabolism? Arterioscler Thromb Vasc Biol 2003; 23: 3-5

41 McCully KS. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr 2007; 86: 15638-15685

42 Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Ceronre R, Fowler B, Grohe H, Schmidt H. The natural history of homocystinuria due to cystathionine –β-synthase deficiency. Am Hum Genet 1985; 37:1-31

43 Yap S, Boers HH, Wilcken B, Wilcken DE, Brenton DP, Lee OJ, Walter JH, Haward PM, Naughten ER. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 2001; 21: 2080-2085

44 Rodionov RN, Lentz SR. The homocysteine paradox. Arterioscler Thromb Vasc Biol 2008; 28:1031-1033

45 Rim YI. Folic acid fortification and supplementation—Good for some but not so good others. Nutrition Rev 2007; 65: 504-511

46 Ulrich CM, Grady WM. Linking epidemiology to epigenomics—where are we today? Cancer Prev Res (Philad) 2010; 3: 1505-1508

47 Tomaszewki JJ, Cummings JL, Parwani AV, Dhir R, Mason JB, Nelson JB, Bacich DJ, O’Keefe DS. Increased cancer cell proliferation in prostate cancer patients with high levels of serum folate. Prostate 2011; 71: 1287-1293

Peer reviewers: Yung-Hsiang Chen, Ph.D., Graduate Institute of Integrated Medicine, China Medical University, No. 91, Hsueh-Shih Road, Taichung 40402, Taiwan; Ezequiel Álvarez Castro, Laboratorio no. 6., Instituto de Investigación Sanitaria de Santiago (IDIS), Edif. Consultas Externas (planta -2), Hospital Clínico Universitario de Santiago, c/Travesía de la Choupana s/n, 15706 Santiago de Compostela, Spain.